KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Deffered Revenue (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Non-Current Deffered Revenue data on record, last reported at $208.7 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue rose 12.39% year-over-year to $208.7 million; the TTM value through Dec 2025 reached $208.7 million, up 12.39%, while the annual FY2025 figure was $208.7 million, 12.39% up from the prior year.
  • Non-Current Deffered Revenue reached $208.7 million in Q4 2025 per REGN's latest filing, down from $219.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $219.2 million in Q3 2025 and bottomed at $27.0 million in Q1 2021.
  • Average Non-Current Deffered Revenue over 5 years is $128.4 million, with a median of $125.3 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: decreased 24.33% in 2021, then skyrocketed 155.22% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $56.5 million in 2021, then rose by 23.54% to $69.8 million in 2022, then skyrocketed by 81.52% to $126.7 million in 2023, then soared by 46.57% to $185.7 million in 2024, then increased by 12.39% to $208.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $208.7 million in Q4 2025, $219.2 million in Q3 2025, and $206.3 million in Q2 2025.